Advanced search×

Drug Discovery Today

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
CSA, Rcgp, Proquest, Sciencedirect from 1996, Gale, and Ingenta

  1. Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer.

    Drug Discovery Today 19(10):1671 (2014) PMID 24928031

  2. New advances in treating thrombotic diseases.

    Drug Discovery Today 19(9):1433 (2014) PMID 24959954

  3. Assessment of right ventricular responses to therapy in pulmonary hypertension.

    Drug Discovery Today 19(8):1246 (2014) PMID 24637045

    Irrespective of its cause, pulmonary hypertension (PH) leads to an increase in pulmonary vascular resistance (PVR). Failing adaption of the right ventricle (RV) to the increased afterload is the main cause of death in PH patients and therefore monitoring RV function during treatment is essential. Ho...
  4. Targeting IL-34 in chronic inflammation.

    Drug Discovery Today 19(8):1212 (2014) PMID 24906044

    A second ligand for colony-stimulating factor-1 receptor (CSF-1R) with distinct biologic activities had long been implicated but not appreciated until the recent discovery of interleukin (IL)-34. IL-34 and CSF-1 signal through this common receptor to mediate the biology of mononuclear phagocytic cel...
  5. The promising trajectory of autism therapeutics discovery.

    Drug Discovery Today 19(7):838 (2014) PMID 24362109

    Pharmacological interventions for neurodevelopmental disorders are increasingly tractable. Autism is a neurodevelopmental disorder that affects approximately 1% of the population. Currently, the standard of care is early behavioral therapy. No approved medical treatments for the diagnostic symptoms...
  6. Dynamic epigenetic responses to muscle contraction.

    Drug Discovery Today 19(7):1010 (2014) PMID 24631681

    Skeletal muscle is a malleable organ that responds to a single acute exercise bout by inducing the expression of genes involved in structural, metabolic and functional adaptations. Several epigenetic mechanisms including histone H4 deacetylation and loss of promoter methylation have been implicated...
  7. Mechanisms of exercise-induced cardiac growth.

    Drug Discovery Today 19(7):1003 (2014) PMID 24637046

    Exercise is a well-established intervention for the prevention and treatment of cardiovascular disease. Increase in cardiomyocyte size is likely to be the central mechanism of exercise-induced cardiac growth, but recent research also supports a role for the generation of new cardiomyocytes as a cont...
  8. Current status and future prospects of toxicogenomics in drug discovery.

    Drug Discovery Today 19(5):562 (2014) PMID 24216320

    In drug discovery and development (DDD), the efficacy, safety and cost of new chemical entities are the main concerns of the pharmaceutical industry. Continuously updated and stricter recommendations imposed by regulatory authorities result in greater challenges being faced by the industry. Reliable...
  9. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations.

    Drug Discovery Today 19(4):400 (2014) PMID 24120893

    The low therapeutic efficacy exhibited by conventional ophthalmic solutions owing to precorneal elimination of the drug, drainage by gravity, nasolacrimal drainage, conjunctival absorption, and the absence of controlled release and of bioadhesive properties, can be overcome by the use of in situ gel...
  10. The end of KRAS, and other, cancers? A new way forward.

    Drug Discovery Today 19(4):383 (2014) PMID 24291216

    Mutant KRAS, as well as other mutant driver genes and epidriver genes, is a dominant determinant of resistance to cancer therapeutics. The recent introduction of targeting therapies based on drugs that inhibit the kinase catalytic function of nodal points along the Ras/extracellular-signal-regulated...